Want to see FR:ALTME full AI Analyst Report?
Top Page
TME Pharma N.V.
(ALTME)
Select Model
Select Model
Rating:48Neutral
Price Target:
€0.14
▲(6.15% Upside)
Action:Reiterated
Date:10/30/26
The score is held down primarily by weak financial performance (pre-commercial revenue profile, ongoing losses, negative free cash flow, and negative equity with rising debt), which implies elevated financing risk. This is only partially offset by moderately positive technical momentum (price above key moving averages and positive MACD). Valuation remains challenging to assess favorably due to negative earnings (negative P/E) and no dividend yield.
Positive Factors
Focused oncology development platform
A concentrated focus on cancer drug development, with particular attention to CNS malignancies, gives the company a defined strategic direction. Advancing candidates through preclinical, clinical, and translational work could support future commercialization or partnering if development milestones are achieved.
Negative Factors
Pre-commercial revenue base
A near-zero or absent revenue base means the company currently lacks recurring commercial inflows to fund operations. This leaves financial progress dependent on successful clinical development and future commercialization or partnering rather than an established revenue engine.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused oncology development platform
A concentrated focus on cancer drug development, with particular attention to CNS malignancies, gives the company a defined strategic direction. Advancing candidates through preclinical, clinical, and translational work could support future commercialization or partnering if development milestones are achieved.
Read all positive factors
TME Pharma N.V. (ALTME) vs. iShares MSCI France ETF (EWQ)
Market Cap
€11.77M
Dividend YieldN/A
Average Volume (3M)1.15M
Price to Earnings (P/E)―
Beta (1Y)-0.69
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding94,988,980
10 Day Avg. Volume893,945
30 Day Avg. Volume1,145,255
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.89
Price to Sales (P/S)0.00
P/FCF Ratio-1.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
TME Pharma N.V. Business Overview & Revenue Model
Company Description
TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipe...
How the Company Makes Money
Public, company-specific detail sufficient to describe TME Pharma N.V.’s revenue model and key revenue streams in a factual way is not available in the provided prompt context; therefore: null...
TME Pharma N.V. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
22
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 19.00K | 17.00K | 0.00 | 33.00K |
| Gross Profit | -8.00K | -78.00K | -127.00K | -92.00K | -65.97K |
| EBITDA | -2.90M | -5.17M | -5.07M | -11.63M | -12.88M |
| Net Income | -3.29M | -5.72M | -6.74M | -15.13M | -14.45M |
Balance Sheet | |||||
| Total Assets | 2.14M | 3.41M | 2.49M | 5.24M | 9.77M |
| Cash, Cash Equivalents and Short-Term Investments | 2.02M | 3.25M | 2.25M | 4.63M | 9.48M |
| Total Debt | 2.39M | 56.00K | 1.17M | 4.09M | 2.44M |
| Total Liabilities | 3.72M | 1.79M | 2.79M | 6.51M | 5.27M |
| Stockholders Equity | -1.58M | 1.61M | -294.00K | -1.27M | 4.51M |
Cash Flow | |||||
| Free Cash Flow | -3.42M | -4.65M | -5.65M | -12.16M | -12.39M |
| Operating Cash Flow | -3.42M | -4.63M | -5.63M | -12.14M | -12.38M |
| Investing Cash Flow | 8.00K | -21.00K | -19.00K | -21.00K | -14.00K |
| Financing Cash Flow | 2.18M | 5.66M | 3.27M | 7.29M | 11.50M |
TME Pharma N.V. Technical Analysis
Positive
0.13
Price Trends
0.12
Positive
0.09
Positive
0.08
Positive
Market Momentum
<0.01
Negative
64.91
Neutral
64.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTME, the sentiment is Positive. The current price of 0.13 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.12, and above the 200-day MA of 0.08, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 64.91 is Neutral, neither overbought nor oversold. The STOCH value of 64.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALTME.
TME Pharma N.V. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | €11.77M | -3.55 | 305.72% | ― | ― | ― | |
47 Neutral | €140.30M | -2.46 | 152.56% | ― | -29.48% | 7.91% | |
47 Neutral | €202.03M | -4.34 | -29.36% | ― | 189.81% | 38.50% | |
46 Neutral | €1.43B | -25.56 | 89.71% | ― | ― | ― | |
43 Neutral | €45.93M | -1.16 | -96.73% | ― | -96.25% | -197.89% | |
43 Neutral | €75.07M | -1.77 | -94.14% | ― | -5.98% | -8.67% |
* Healthcare Sector Average
FR:ALTME
TME Pharma N.V.
0.12
0.03
26.53%
FR:IPH
Innate Pharma SA
1.26
-0.42
-24.88%
FR:NANO
Nanobiotix
28.12
10.22
57.09%
FR:TNG
Transgene
0.73
-0.61
-45.82%
FR:OSE
OSE Immunotherapeutics SA
1.95
-3.97
-67.05%
FR:ALCLS
Cellectis SA
1.04
-2.05
-66.35%
TME Pharma N.V. Corporate Events
TME Pharma Secures Exclusive Talks With Japan’s TMS to Advance NOX-A12 Glioblastoma Program
Oct 29, 2026
TME Pharma has entered into an exclusive six-month negotiation agreement with Japanese clinical-stage biotech TMS Co., which will form a dedicated subsidiary to finance and advance global development of NOX-A12 for glioblastoma. The non-binding fr...
TME Pharma Extends Debt Maturity and Secures New Bond Financing to 2028
Oct 26, 2026
TME Pharma has extended the maturity of all its outstanding debt from May 2027 to 30 June 2028 and secured two new bond financings, improving financial visibility until the second quarter of 2028. The company is favoring bond over equity funding t...
TME Pharma CEO Emphasizes Cash Discipline and Strategic Partnering for Lead Cancer Asset
Sep 16, 2026
TME Pharma, a clinical-stage biotech group developing therapies for brain cancer and eye diseases, is centered on two key RNA aptamer assets targeting the tumor microenvironment and fibrotic pathways. The firm is advancing its NOX-A12 program in g...
TME Pharma moves to license glioblastoma drug NOX-A12 and widens strategic focus
Aug 24, 2026
TME Pharma is advancing late-stage partnering plans for its flagship oncology drug NOX-A12, entering a final evaluation phase with two potential partners for a licensing deal to fund and run a phase 2 trial in glioblastoma. The asset benefits from...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.